Canaccord Genuity Reiterates Buy on Globus Medical, Maintains $79 Price Target
Portfolio Pulse from Benzinga Newsdesk
Canaccord Genuity analyst Caitlin Cronin reiterates a Buy rating on Globus Medical (NYSE:GMED) and maintains a $79 price target.
February 21, 2024 | 2:05 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Canaccord Genuity analyst Caitlin Cronin reiterates a Buy rating on Globus Medical and maintains a $79 price target.
The reiteration of a Buy rating and maintenance of a $79 price target by a reputable analyst like Caitlin Cronin from Canaccord Genuity is likely to instill confidence among investors and could positively influence the short-term stock price movement of Globus Medical.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100